News
ME
0.4671
-5.39%
-0.0266
23andMe To Present Preliminary Efficacy And Biomarker Data For 23ME-00610 At The 2024 ASCO Annual Meeting
23andMe has accepted two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, for poster presentations at the 2024 ASCO Annual Meeting in Chicago. 23andMe scientists discovered the target for 23ME -00610 through the company's proprietary database of human genetic and health information. The antibody is in the Phase 1/2a clinical development for advanced cancer.
Benzinga · 1d ago
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting in Chicago. 23andMe will present clinical data for the neuroendocrine and ovarian cancer patient cohorts.
Barchart · 1d ago
PETROS PHARMACEUTICALS INC: NEW COLLABORATION WITH LEMONAID HEALTH
Reuters · 2d ago
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Spatial technology company Matterport has agreed to be acquired by real estate giant CoStar. Nextdoor and genetics company 23andMe are two other ex-SPACs that could be acquired. The social media platform Nextdoor is losing money and is in danger of being delisted from the Nasdaq. 23andme's in-home genetics testing company is also losing money.
The Motley Fool · 2d ago
Weekly Report: what happened at ME last week (0415-0419)?
Weekly Report · 3d ago
23andMe CEO Anne Wojcicki Says She's Weighing Buyout Bid
23andMe founder and CEO Anne Wojcicki has offered to take the DNA testing company private. 23andMe's stock was down 4.2% on Friday. The company has lost 97% of its value since going public in June 2021. The DNA-testing company had revenue of $44.7 million in the third quarter.
Barron‘s · 6d ago
Column: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Ask class members.
Alison Frankel: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Frankel says plaintiffs have a say in picking lawyers to lead consolidated cases. She says firm hired professors to survey prospective class members about what they want. Franelson says class members want transparency, a quick settlement, a lean, efficient leadership team.
Reuters · 04/18 22:37
Health Care Sector Update for 04/18/2024: TGTX, ME, ELV, BNTC
NASDAQ · 04/18 19:53
Nasdaq Down 0.5%; Lithium Americas Shares Slide
U.S. Stocks traded mostly lower toward the end of trading on Thursday. The Dow traded down 0.01% while the NASDAQ Composite fell around 0.5%. D.R. Horton, Inc. Reported better-than-expected second-quarter financial results. Asian markets closed mostly higher in Asia Pacific markets.
Benzinga · 04/18 18:54
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 04/18 16:32
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. Aileron Therapeutics (NASdaq:ALRN) and 23andMe Holding moved upwards. Losers SeaStar Medical Holding and Aptorum Gr stock decreased by 27.0% during the session.
Benzinga · 04/18 16:31
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
U.S. Stocks traded higher midway through trading on Thursday. The Dow traded up 0.64% while the S&P 500 gained around 0.5%. D.R. Horton, Inc. Reported better-than-expected second-quarter financial results. Asian markets closed mostly higher in Asia Pacific markets. European shares were higher today.
Benzinga · 04/18 16:08
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Anne Wojcicki, co-founder and chief executive of 23andMe Holding Co, is contemplating taking the genetics testing company private. The company went public in 2021 and was valued at $3.5 billion. 23andme reported revenue of $44.7 million in the third quarter of fiscal 2024.
Benzinga · 04/18 16:06
Thursday Sector Leaders: General Contractors & Builders, Diagnostics
NASDAQ · 04/18 16:01
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Las Vegas Sands Corp. Shares dipped 6.8% to $46.81 on Thursday. The company reported better-than-expected first-quarter results. AGBA Group Holding Limited shares jumped 148% after the company announced a merger agreement with Triller. Other stocks moving in the mid-day session included 23andMe Holding Co. And Vertex Pharmaceuticals.
Benzinga · 04/18 15:32
Why Is Lithium Americas (LAC) Stock Down 28% Today?
Lithium Americas (NYSE:LAC) stock is falling hard on Thursday after the lithium mining company announced the pricing for a public offering of its shares. Lithium Americas is offering 55 million shares of LAC stock for $5 each in this offering. The company expects gross proceeds of $275 million from this stock offering. LAC shares are down 27.5% as of Thursday morning.
Investorplace · 04/18 15:07
Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
Shares of 23andMe (NASDAQ:ME), Bio-Path (NASdaq:BPTH) and AGBA Group ( NASDAQ:AGBA) stock are moving today. Walgreens is cutting jobs at its Chicago facilities. The company is also reducing workers’ hours as part of its efforts to reduce operating costs. WBA stock is largely unmoved as of Thursday morning.
Investorplace · 04/18 14:56
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe stock is up 40% as of Thursday morning. The 23andMe CEO is working on a plan to take the company private. The company only went public in 2021. Shares of Bio-Path stock are up 89% and AGBA Group is up 149% today.
Investorplace · 04/18 14:44
More
Webull provides a variety of real-time ME stock news. You can receive the latest news about 23Andme Holding Co through multiple platforms. This information may help you make smarter investment decisions.
About ME
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.